Alan Sebulsky bought $250K of Parabilis Medicines (PBLS)
Executed Jun 11, disclosed Jun 15, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Jun 15), the stock returned +11.6% (delay-adjusted); from the execution session (Jun 11), -1.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Alan Sebulsky (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Parabilis Medicines, Inc. (PBLS). Across 2 priced purchase filings, the average 21-session return was +1.5% from execution and +13.3% from disclosure (delay-adjusted; derived). The largest single filing was $474K of PBLS (17,500 sh across 3 lots, as filed), executed Jun 12.
Healthcare · Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for dis…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→17,500 sh across 3 lots
Exec Jun 12
Filed Jun 16 · 6:19 PM ET